Atara Biotherapeutics Company Insiders
| ATRA Stock | USD 0.69 0.02 2.82% |
About 72% of Atara Biotherapeutics' corporate insiders are selling. The analysis of the overall insider sentiment regarding Atara Biotherapeutics suggests that many insiders are alarmed. Atara Biotherapeutics employs about 225 people. The company is managed by 35 executives with a total tenure of roughly 158 years, averaging almost 4.0 years of service per executive, having 6.43 employees per reported executive.
| Pascal Touchon CEO President CEO, Director |
| Isaac Ciechanover CEO President CEO, Director |
Atara Biotherapeutics' Insider Buying Vs Selling
28
Selling | Buying |
Latest Trades
| 2024-03-04 | Pascal Touchon | Disposed 24844 @ 0.72 | View | ||
| 2023-11-16 | Pascal Touchon | Disposed 20409 @ 0.39 | View | ||
| 2023-11-13 | Carol Giltner Gallagher | Acquired 179020 @ 0.22 | View | ||
| 2023-11-10 | William K Heiden | Acquired 100000 @ 0.25 | View | ||
| 2023-08-16 | Pascal Touchon | Disposed 30766 @ 1.65 | View | ||
| 2023-06-27 | Pascal Touchon | Disposed 14291 @ 1.66 | View | ||
| 2023-05-16 | Pascal Touchon | Disposed 29766 @ 2.04 | View |
Monitoring Atara Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Atara |
Atara Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6211) % which means that it has lost $0.6211 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.92, whereas Return On Tangible Assets are projected to grow to (1.58). At present, Atara Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.1 M, whereas Non Current Assets Total are forecasted to decline to about 44.3 M.The current year's Common Stock Shares Outstanding is expected to grow to about 111.2 M, whereas Net Loss is forecasted to decline to (215.7 M).
Atara Biotherapeutics Workforce Comparison
Atara Biotherapeutics is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 693. Atara Biotherapeutics totals roughly 225 in number of employees claiming about 32% of equities under Health Care industry.
Atara Biotherapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atara Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mallik Ameet over two weeks ago Acquisition by Mallik Ameet of 150000 shares of Atara Biotherapeutics subject to Rule 16b-3 | ||
Jill Henrich over a month ago Disposition of 3879 shares by Jill Henrich of Atara Biotherapeutics at 0.72 subject to Rule 16b-3 | ||
Jill Henrich over a month ago Disposition of 3879 shares by Jill Henrich of Atara Biotherapeutics at 0.72 subject to Rule 16b-3 | ||
Pascal Touchon over three months ago Acquisition by Pascal Touchon of 1280000 shares of Atara Biotherapeutics subject to Rule 16b-3 | ||
Pascal Touchon over three months ago Sale by Pascal Touchon of 20409 shares of Atara Biotherapeutics | ||
Pascal Touchon over six months ago Sale by Pascal Touchon of 21432 shares of Atara Biotherapeutics | ||
Gad Soffer over a year ago Exercise or conversion by Gad Soffer of 4145 shares of Atara Biotherapeutics subject to Rule 16b-3 | ||
Pascal Touchon over a year ago Sale by Pascal Touchon of 15679 shares of Atara Biotherapeutics |
Atara Biotherapeutics Notable Stakeholders
An Atara Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atara Biotherapeutics often face trade-offs trying to please all of them. Atara Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atara Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pascal Touchon | President CEO, Director | Profile | |
| Isaac Ciechanover | President CEO, Director | Profile | |
| Pascal DVM | CEO President | Profile | |
| John Craighead | Vice President Investor Relations | Profile | |
| Derrell Porter | Senior Vice President Head of Commercial | Profile | |
| Joseph Newell | Executive Vice President Chief Technical Operations Officer | Profile | |
| Heather Turner | Executive Vice President General Counsel, Secretary and Head of Portfolio Strategy | Profile | |
| Mina Kim | Senior Vice President General Counsel, Secretary | Profile | |
| Kanya Rajangam | Senior Vice President Chief Medical Officer | Profile | |
| Utpal Koppikar | CFO | Profile | |
| John McGrath | CFO and Secretary | Profile | |
| Gad Soffer | COO | Profile | |
| Roy Baynes | Independent Director | Profile | |
| Carol Gallagher | Lead Independent Director | Profile | |
| Eric Dobmeier | Director | Profile | |
| William Heiden | Independent Director | Profile | |
| Matthew Fust | Independent Director | Profile | |
| Beth Seidenberg | Independent Director | Profile | |
| Joel Marcus | Independent Director | Profile | |
| Rajani MD | Senior Officer | Profile | |
| Kerry Daly | Head Communications | Profile | |
| Jill Henrich | Executive Quality | Profile | |
| Alex Chapman | Vice Relations | Profile | |
| Charlene Banard | Chief Officer | Profile | |
| Amar Murugan | Executive Officer | Profile | |
| Dietmar Berger | Global Head of Research and Development | Profile | |
| Dan Maziasz | Executive Officer | Profile | |
| Eric Hyllengren | Executive Officer | Profile | |
| Jakob MD | Ex RD | Profile | |
| Christopher Haqq | Chief Medical Officer | Profile | |
| Utpal MBA | Ex CFO | Profile | |
| Anhco Nguyen | Executive Officer | Profile | |
| Manher MD | Executive Officer | Profile | |
| Mitchall Clark | Chief Regulatory and Quality Assurance Officer | Profile | |
| Amie Krause | Chief Officer | Profile |
About Atara Biotherapeutics Management Performance
The success or failure of an entity such as Atara Biotherapeutics often depends on how effective the management is. Atara Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.67) | (1.58) | |
| Return On Capital Employed | (11.57) | (10.99) | |
| Return On Assets | (1.67) | (1.58) | |
| Return On Equity | 2.78 | 2.92 |
The data published in Atara Biotherapeutics' official financial statements usually reflect Atara Biotherapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Atara Biotherapeutics. For example, before you start analyzing numbers published by Atara accountants, it's critical to develop an understanding of what Atara Biotherapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Atara Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atara Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.
Atara Biotherapeutics Workforce Analysis
Traditionally, organizations such as Atara Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atara Biotherapeutics within its industry.Atara Biotherapeutics Manpower Efficiency
Return on Atara Biotherapeutics Manpower
| Revenue Per Employee | 38.1K | |
| Revenue Per Executive | 244.9K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 7.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Revenue Per Share 0.081 | Quarterly Revenue Growth 13.457 | Return On Assets (0.62) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.